Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from CanSino Biologics, Inc. Class H ( (HK:6185) ) is now available.
CanSino Biologics Inc. announced the approval of its Phase I clinical trial for an inhaled tuberculosis booster vaccine in Indonesia. This development is significant as it addresses the limitations of the existing Bacillus Calmette-Guerin vaccine by offering a booster that enhances mucosal immunity, potentially improving tuberculosis prevention efforts in high-burden regions.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, focusing on the development of vaccines. It has a notable presence in the pharmaceutical industry with a particular emphasis on innovative vaccine solutions, including those for tuberculosis and COVID-19.
Average Trading Volume: 1,664,272
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.81B
For a thorough assessment of 6185 stock, go to TipRanks’ Stock Analysis page.